KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

BeOne Medicines (ONC) Receivables - Other (2017 - 2023)

BeOne Medicines (ONC) has disclosed Receivables - Other for 7 consecutive years, with $1.7 million as the latest value for Q4 2023.

  • On a quarterly basis, Receivables - Other fell 42.91% to $1.7 million in Q4 2023 year-over-year; TTM through Dec 2023 was $1.7 million, a 42.91% decrease, with the full-year FY2023 number at $1.7 million, down 42.91% from a year prior.
  • Receivables - Other was $1.7 million for Q4 2023 at BeOne Medicines, up from $1.6 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $12.7 million in Q4 2020 to a low of $1.3 million in Q1 2023.
  • A 5-year average of $4.7 million and a median of $5.1 million in 2021 define the central range for Receivables - Other.
  • Peak YoY movement for Receivables - Other: skyrocketed 133.09% in 2019, then tumbled 74.81% in 2023.
  • BeOne Medicines' Receivables - Other stood at $6.1 million in 2019, then skyrocketed by 106.92% to $12.7 million in 2020, then crashed by 60.07% to $5.1 million in 2021, then crashed by 39.85% to $3.0 million in 2022, then plummeted by 42.91% to $1.7 million in 2023.
  • Per Business Quant, the three most recent readings for ONC's Receivables - Other are $1.7 million (Q4 2023), $1.6 million (Q3 2023), and $2.0 million (Q2 2023).